If you click through a couple of screens, this is what you will find. Looks like Dr. Kelly will have an opportunity to discuss Leronlimab applications beyond NASH.

---

Driving Innovation in Patient Selection: Rethinking Inclusion & Exclusion Criteria

Time: 2:00 pm
Day: Day 2 Stream 2 PM

Details:

Investigating clinical trials for NASH in HIV-infected patients

Evaluating novel biomarker outcomes in NASH and considering comorbidities

Beyond NASH: driving studies in cardiovascular and metabolic disorders

Speakers:
Scott Kelly